MeiraGTx (MGTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of three directors: Ellen Hukkelhoven, Nicole Seligman, and Debra Yu.
Proposal to ratify Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be transacted as properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and the auditor ratification.
Audit committee and external auditor matters
Ernst & Young LLP is proposed for ratification as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MeiraGTx
- Late-stage pipeline, transformative gene therapies, and strong partnerships drive near-term approvals.MGTX
Corporate presentation - Q2 2026 net income of $160.7M on $321.4M revenue, fueled by licensing, acquisitions, and clinical progress.MGTXQ2 2026
- Directors and auditor were elected and ratified, with no shareholder questions submitted.MGTXAGM 2026
- Late-stage gene therapies advance with pivotal xerostomia data, XLRP filings, and major partnerships.MGTXJefferies Global Healthcare Conference 2026
- Late-stage pipeline and riboswitch platform drive transformative therapies for major unmet needs.MGTXCorporate presentation
- Regained RPGR rights and late-stage pipeline progress position for near-term commercialization.MGTXBank of America Global Healthcare Conference 2026
- Q1 2026 net loss rose to $46.3M; FDA breakthrough, bota-vec deal, and $100M raise drive pipeline.MGTXQ1 2026
- Director elections, auditor ratification, and robust governance highlight this year's proxy.MGTXProxy filing
- Gene therapy restored vision and quality of life in all 11 LCA4 children, with lasting benefit.MGTXStudy Update